Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

INVITAE CORPORATION

(NVTA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Invitae : Ciitizen Announcement Conference Call Presentation

09/07/2021 | 11:52am EDT

+

From genetics, health

Acquisition and platform update 09 | 07 | 21

Safe harbor statement

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company's beliefs regarding the potential benefits of its pending acquisition of Ciitizen; the expected transaction terms; the company's beliefs regarding its business and business strategy; and the benefits and importance of the company's acquisitions and collaborations. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the closing of the pending acquisition of Ciitizen; the ability of the company to achieve the expected benefits of the acquisition; the impact of COVID- 19 on the company, and the effectiveness of the efforts it has taken or may take in the future in response thereto; the company's ability to continue to grow its business, including internationally; the ability to maintain important customer relationships; the company's ability to compete; the company's failure to manage growth effectively; the company's need to scale its infrastructure in advance of demand for its tests and to increase demand for its tests; the risk that the company may not obtain or maintain sufficient levels of reimbursement for its tests; the company's ability to obtain regulatory approval for its tests; the company's failure to successfully integrate or fully realize the anticipated benefits of acquired businesses; risks associated with litigation; the company's ability to use rapidly changing genetic data to interpret test results accurately and consistently; the applicability of clinical research results to actual outcomes; the success of collaborations; security breaches, loss of data and other disruptions; laws and regulations applicable to the company's business; and the other risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2021. These forward-looking statements speak only as of the date hereof, and Invitae Corporation disclaims any obligation to update these forward-looking statements.

© 2021 Invitae Corporation. All Rights Reserved.

2

Single greatest shift in medicine and healthcare

"Modern" medicine

Chemotherapy standard of care Newborn diagnosis after birth

Symptom-based, universally applied

© 2021 Invitae Corporation. All Rights Reserved.

Universal testing for all

Risk information = effective prevention

Earliest detection - disease eradication

Personalized therapy and biomarker driven monitoring

Gene informed healthcare throughout life

3

Invitae's mission and core data tenets

Patients own

Health data

is more

their health

valuable

data

when shared

© 2021 Invitae Corporation. All Rights Reserved.

4

  1. patient-mediatedplatform for data sharing
  1. patient-mediated platform that allows patients to collect and store their medical records, and turns documents into usable, computable and relevant longitudinal data that can be shared with whomever they consent

© 2021 Invitae Corporation. All Rights Reserved.

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Invitae Corporation published this content on 07 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 07 September 2021 15:51:06 UTC.


© Publicnow 2021
All news about INVITAE CORPORATION
09/25INVITAE : New Study Highlights the Value of Genetic Testing to Guide Clinical Management a..
PR
09/24INSIDER SELL : Invitae
MT
09/09VC DAILY : Digital Health Is Booming, but VC Doesn't See a Bubble Forming
DJ
09/07INVITAE : Ciitizen Announcement Conference Call Presentation
PU
09/07INVITAE : — Combination to bring together the power of genomic and clinical informati..
PU
09/07INVITAE CORP : Unregistered Sale of Equity Securities, Regulation FD Disclosure, Other Eve..
AQ
09/07INVITAE : to Acquire Consumer Health Tech Company Ciitizen in $325 Million Deal
MT
09/07INVITAE : to Acquire Ciitizen to Strengthen its Patient-Consented Health Data Platform to ..
PR
09/07Invitae Corporation entered into definitive agreement to acquire Ciitizen Corporation f..
CI
09/01INVITAE : to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
PR
More news
Analyst Recommendations on INVITAE CORPORATION
More recommendations
Financials (USD)
Sales 2021 485 M - -
Net income 2021 -523 M - -
Net Debt 2021 342 M - -
P/E ratio 2021 -10,8x
Yield 2021 -
Capitalization 5 977 M 5 977 M -
EV / Sales 2021 13,0x
EV / Sales 2022 9,42x
Nbr of Employees 2 600
Free-Float 96,9%
Chart INVITAE CORPORATION
Duration : Period :
Invitae Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INVITAE CORPORATION
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 27,50 $
Average target price 40,44 $
Spread / Average Target 47,1%
EPS Revisions
Managers and Directors
Sean Emerson George Chairman, President & Chief Executive Officer
Roxi Wen Chief Financial Officer
Robert Nussbaum Chief Medical Officer
Eric Olivares Chief Science Officer
Layton Wedgeworth Chief Technology Officer
Sector and Competitors